| ZAI-LAB |
ZAI-LAB |
90%
|
In August 2025, the Company entered into a material transfer agreement (the “MTA”) with Zai Lab, to supply certain materials for clinical trial use in exchange for a fixed payment. |
| ZENAS-BIOPHARMA |
ZENAS-BIOPHARMA |
80%
|
The Side Agreement and MTA were evaluated under ASC 606, Revenue from Contracts with Customers, and determined to be contract modifications to the Zenas Agreements. |
| CRNX |
Crinetics Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from CRNX graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from VRDN graph: ts • substantial costs of litigatio… |
| CRNX |
Crinetics Pharmaceuticals, Inc. |
72%
|
ts • substantial costs of litigation, including monetary awards to patients or other claimants; • liabilities that substantially exceed our product liability insurance, which we would then be require… |
| HTGC |
Hercules Capital, Inc. |
72%
|
Reciprocal relationship from HTGC graph: Reciprocal relationship from VRDN graph: Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q, we may require significant additional capital earlier … |
| HTGC |
Hercules Capital, Inc. |
72%
|
Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q, we may require significant additional capital earlier than we currently expect under our present business plans. Loan and Security Agree… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from JNJ grap… |
| JNJ |
Johnson & Johnson |
72%
|
ts • substantial costs of litigation, including monetary awards to patients or other claimants; • liabilities that substantially exceed our product liability insurance, which we would then be require… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from MYGN g… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
he development of our product candidates, our financial condition, results of operations and business prospects. In addition, it may be difficult or impossible to obtain certain source documentation … |
| ZBIO |
Zenas BioPharma, Inc. |
72%
|
Reciprocal relationship from ZBIO graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from ZBIO g… |
| ZBIO |
Zenas BioPharma, Inc. |
72%
|
estimate of future cash flows includes estimated future Net Sales Royalties to be paid to DRI and the receipt of conditional payments from DRI that were deemed probable of achievement at inception. T… |
| AMGEN-ARGENX-IMMUNOVANT-INC-ROCHE-HOLDINGS-AG-AC |
AMGEN-ARGENX-IMMUNOVANT-INC-ROCHE-HOLDINGS-AG-AC |
62%
|
ts • substantial costs of litigation, including monetary awards to patients or other claimants; • liabilities that substantially exceed our product liability insurance, which we would then be require… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
ercial activities for veligrotug and our growing organization; and • $9.1 million increase in legal services, market research and other professional and consulting fees primarily for preparatory comm… |
| CAYMAN-LIMITED |
CAYMAN-LIMITED |
62%
|
estimate of future cash flows includes estimated future Net Sales Royalties to be paid to DRI and the receipt of conditional payments from DRI that were deemed probable of achievement at inception. T… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
erally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax att… |
| ENABLE-INJECTIONS-INC |
ENABLE-INJECTIONS-INC |
62%
|
ompany of $ 70.0 million. Additionally, the Company is eligible to receive up to an additional $ 315.0 million of non-refundable milestone payments upon achieving specific milestone events during the… |
| FAIRMOUNT-FUNDS-MANAGEMENT-LLC |
FAIRMOUNT-FUNDS-MANAGEMENT-LLC |
62%
|
Lab (the “Side Agreement”), with Zenas BioPharma as countersigner, pursuant to which the Company agreed to provide certain services directly to Zai Lab to support development and commercialization ac… |
| HONG-KONG-LIMITED |
HONG-KONG-LIMITED |
62%
|
ndition, results of operations and growth prospects. We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, including Chinese manufacturer WuXi Biologic… |
| KISSEI-PHARMACEUTICAL-CO-LTD |
KISSEI-PHARMACEUTICAL-CO-LTD |
62%
|
Lab (the “Side Agreement”), with Zenas BioPharma as countersigner, pursuant to which the Company agreed to provide certain services directly to Zai Lab to support development and commercialization ac… |
| PARAGON-THERAPEUTICS-INC |
PARAGON-THERAPEUTICS-INC |
62%
|
Lab (the “Side Agreement”), with Zenas BioPharma as countersigner, pursuant to which the Company agreed to provide certain services directly to Zai Lab to support development and commercialization ac… |
| PROMETHEUS-LABORATORIES-INC |
PROMETHEUS-LABORATORIES-INC |
62%
|
he development of our product candidates, our financial condition, results of operations and business prospects. In addition, it may be difficult or impossible to obtain certain source documentation … |
| SLING-THERAPEUTICS-INC |
SLING-THERAPEUTICS-INC |
62%
|
ts • substantial costs of litigation, including monetary awards to patients or other claimants; • liabilities that substantially exceed our product liability insurance, which we would then be require… |
| SLNG |
Stabilis Solutions, Inc. |
62%
|
Reciprocal relationship from SLNG graph: Reciprocal relationship from VRDN graph: ts • substantial costs of litigation, including monetary awards to patients or other claimants; • liabilities that su… |
| TOURMALINE-BIO-INC |
TOURMALINE-BIO-INC |
62%
|
ts • substantial costs of litigation, including monetary awards to patients or other claimants; • liabilities that substantially exceed our product liability insurance, which we would then be require… |
